A Study of Pharmacokinetics, Safety and Tolerability of Dimolegin (DD217)
Status:
Completed
Trial end date:
2018-04-25
Target enrollment:
Participant gender:
Summary
In the course of the clinical study, the pharmacokinetics, pharmacodynamics, safety and
tolerability of Dimolegin (DD217) 10 mg enteric-coated tablets after single administration to
healthy volunteers at increasing doses were studied.
24 volunteers participated in the study. The randomization procedure was carried out for 24
volunteers selected at screening. In Group 1 6 volunteers were randomized , in Group 2 6
volunteers were randomized, and in Group 3 12 volunteers were enrolled. Group 1 volunteers
took the study drug at a dose of 20 mg once, group 2 volunteers took the study drug at a dose
of 40 mg once, and group 3 volunteers took the study drug at a dose of 60 mg once.